EGFR and colorectal carcinoma: Notably, in late-stage CRC patients treated with cetuximab [72] or bevacizumab [73], EGFR inhibition can result in Mg wasting due to decreased renal reabsorption, and a decrease in circulating Mg2+ may act as a predictive factor of treatment efficacy and outcome [74,75].